<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFASALAZINE- sulfasalazine tablet </strong><br>Watson Laboratories, Inc.<br></p></div>
<h1>
<span class="Bold">Sulfasalazine</span><br><span class="Bold">Tablets USP</span><br>Revised: December 2012<br><span class="Bold">Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_dcb92c31-cbe1-48b3-9bea-91fcefb6f3dc"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Sulfasalazine Tablets, USP, 500 mg for oral administration.</p>
<p><span class="Bold">Therapeutic Classification:</span> Anti-inflammatory agent.</p>
<p><span class="Bold">Chemical Designation: </span>5-([<span class="Italics">p</span>-(2-pyridylsulfamoyl)phenyl]azo)salicylic acid.</p>
<p><span class="Bold">Chemical Structure:</span></p>
<div class="Figure"><img alt="Sulfasalazine Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad13d598-7b1b-48d3-a25b-08635b419f99&amp;name=sulfasalazine-tablets-usp-1.jpg"></div>
<p>C<span class="Sub">18</span>H<span class="Sub">14</span>N<span class="Sub">4</span>O<span class="Sub">5</span>S</p>
<p>The molecular weight of sulfasalazine is 398.39.</p>
<p><span class="Bold">Inactive Ingredients: </span>magnesium stearate, pregelatinized starch, sodium starch glycolate and stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_18588787-8f53-4065-93b0-d586b1a25776"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_66ff0b0d-0aad-4967-a143-315a214f059d"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">Pharmacodynamics</span></h2>
<p class="First">The mode of action of sulfasalazine (SSZ) or its metabolites, 5-amino­salicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <span class="Italics">in vitro </span>models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradio-graphic studies in animals. In <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, clinical studies utilizing rectal administration of SSZ, SP, and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_23c5ff52-bec2-49a8-bdb1-ac57d89e5f0d"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">Pharmacokinetics</span></h2>
<p class="First"><span class="Italics">In vivo </span>studies have indicated that the absolute bioavailability of orally administered SSZ is less than 15% for parent drug. In the intestine, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Of the two species, SP is relatively well absorbed from the intestine and highly metabolized, while 5-ASA is much less well absorbed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_67a20140-e350-482b-9959-66de56b7c98f"></a><a name="section-2.2.1"></a><p></p>
<h3>Absorption:</h3>
<p class="First">Following oral administration of 1 g of SSZ to 9 healthy males, less than 15% of a dose of SSZ is absorbed as parent drug. Detectable serum concentrations of SSZ have been found in healthy subjects within 90 minutes after the ingestion. Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.</p>
<p>In comparison, peak plasma levels of both SP and 5-ASA occur approximately 10 hours after dosing. This longer time to peak is indicative of gastrointestinal transit to the lower intestine where bacteria mediated metabolism occurs. SP apparently is well absorbed from the colon with an estimated bioavailability of 60%. In this same study, 5-ASA is much less well absorbed from the gastrointestinal tract with an estimated bioavailability of from 10% to 30%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a763e399-fdf6-4324-bf2d-88f31d7be1ea"></a><a name="section-2.2.2"></a><p></p>
<h3>Distribution:</h3>
<p class="First">Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L. SSZ is highly bound to albumin (&gt;99.3%), while SP is only about 70% bound to albumin. Acetylsulfapyridine (AcSP), the principal metabolite of SP, is approximately 90% bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a702dc15-27ee-4204-a201-241feb1ad327"></a><a name="section-2.2.3"></a><p></p>
<h3>Metabolism:</h3>
<p class="First">As mentioned above, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Approximately 15% of a dose of SSZ is absorbed as parent and is metabolized to some extent in the liver to the same two species. The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours while in slow acetylators, it is 14.8 hours. SP can also be metabolized to 5-hydroxy-sulfapyridine (SPOH) and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolized in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half-life are not possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f6fa832-c34c-4864-b52a-9a4083d32a6c"></a><a name="section-2.2.4"></a><p></p>
<h3>Excretion:</h3>
<p class="First">Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. The calculated clearance of SSZ following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cdbfd064-243b-45ca-83c2-5de3a5f8269c"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">Special Populations</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c9fdb77a-0c55-4f92-9408-686f8342a328"></a><a name="section-2.3.1"></a><p></p>
<h3>Elderly:</h3>
<p class="First">Elderly patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> showed a prolonged plasma half-life for SSZ, SP, and their metabolites. The clinical impact of this is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7d2f21e3-19b2-44c8-9db3-c4749f7007d7"></a><a name="section-2.3.2"></a><p></p>
<h3>Pediatric:</h3>
<p class="First">Small studies have been reported in the literature in children down to the age of 4 years with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>. In these populations, relative to adults, the pharmacokinetics of SSZ and SP correlated poorly with either age or dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f8211dd9-277b-4e67-842c-be8a433ccfe1"></a><a name="section-2.3.3"></a><p></p>
<h3>Acetylator Status:</h3>
<p class="First">The metabolism of SP to AcSP is mediated by polymorphic enzymes such that two distinct populations of slow and fast metabolizers exist. Approximately 60% of the Caucasian population can be classified as belonging to the slow acetylator phenotype. These subjects will display a prolonged plasma half-life for SP (14.8 hours vs 10.4 hours) and an accumulation of higher plasma levels of SP than fast acetylators. The clinical implication of this is unclear; however, in a small pharmacokinetic trial where acetylator status was determined, subjects who were slow acetylators of SP showed a higher incidence of adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e05f28f6-a547-43e6-a538-48ca33ff01da"></a><a name="section-2.3.4"></a><p></p>
<h3>Gender:</h3>
<p class="First">Gender appears not to have an effect on either the rate or the pattern of metabolites of SSZ, SP, or 5-ASA.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_96dd43fa-809d-48b5-b35c-a66cf76c6d87"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Sulfasalazine tablets are indicated:</p>
<ol class="LittleAlpha">
<li>in the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, and as adjunctive therapy in severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; and</li>
<li>for the prolongation of the remission period between acute attacks of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_3b259447-91cb-4f81-888d-afe83da01922"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Sulfasalazine tablets are contraindicated in:</p>
<p>Patients with intestinal or urinary obstruction,<br>Patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> as sulfonamides have been reported to precipitate an acute attack,<br>Patients hypersensitive to sulfasalazine, its metabolites, sulfonamides or salicylates.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_c0fab2a2-13c2-40ed-a40b-6a394bc235b6"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Only after critical appraisal should sulfasalazine tablets be given to patients with hepatic or renal damage or <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> associated with the administration of sulfasalazine have been reported from <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, renal and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, irreversible neuromuscular and central nervous system changes, and <span class="product-label-link" type="condition" conceptid="4025168" conceptname="Diffuse interstitial pulmonary fibrosis">fibrosing alveolitis</span>. The presence of clinical signs such as <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be indications of serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> or hepatotoxicity. Complete blood counts, as well as urinalysis with careful microscopic examination, should be done frequently in patients receiving sulfasalazine (see <a href="#LINK_35351c0f-71d7-48e9-890d-b81a1931bfda">PRECAUTIONS, Laboratory Tests</a>). Discontinue treatment with sulfasalazine while awaiting the results of blood tests. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> have been observed in men treated with sulfasalazine; however, withdrawal of the drug appears to reverse these effects.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_a9f02a18-d52d-42ad-99bf-2800f24c3fc2"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_8d35e5bd-bf5e-4d66-8879-3c220f88bee8"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General:</span></h2>
<p class="First">Sulfasalazine tablets should be given with caution to patients with severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Adequate fluid intake must be maintained in order to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation. Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. This reaction is frequently dose related. If toxic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, the drug should be discontinued immediately.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_87371d21-a2d3-4e97-a12a-b0876038bf29"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Information for Patients:</span></h2>
<p class="First">Patients should be informed of the possibility of adverse reactions and of the need for careful medical supervision. The occurrence of <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may indicate a serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span>. Should any of these occur, the patient should seek medical advice. They should also be made aware that <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> rarely remits completely, and that the risk of relapse can be reduced by continued administration of sulfasalazine at a maintenance dosage. Patients should be instructed to take sulfasalazine in evenly divided doses preferably after meals. Additionally, patients should be advised that sulfasalazine may produce an orange-yellow discoloration of the urine or skin.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_35351c0f-71d7-48e9-890d-b81a1931bfda"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Laboratory Tests:</span></h2>
<p class="First">Complete blood counts, including differential white cell count and liver function tests, should be performed before starting sulfasalazine and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Urinalysis and an assessment of renal function should also be done periodically during treatment with sulfasalazine.</p>
<p>The determination of serum sulfapyridine levels may be useful since concentrations greater than 50 µg/mL appear to be associated with an increased incidence of adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_230a53fd-6eec-4650-bec0-577bc1d4aeb3"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">Drug Interactions:</span></h2>
<p class="First">Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_4ad5d58b-5a74-4d88-bbc8-01dd3ff29918"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Drug/Laboratory Test Interactions:</span></h2>
<p class="First">The presence of sulfasalazine or its metabolites in body fluids has not been reported to interfere with laboratory test procedures.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_5687dd93-c13e-45b1-823f-470bc8d75142"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></h2>
<p class="First">Two-year oral carcinogenicity studies were conducted in male and female F344/N rats and B6C3F1 mice. Sulfasalazine was tested at 84 (496 mg/m²), 168 (991 mg/m²), and 337.5 (1991 mg/m²) mg/kg/day doses in rats. A statistically significant increase in the incidence of urinary bladder transitional cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> was observed in male rats. In female rats, two (4%) of the 337.5 mg/kg rats had transitional cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> of the kidney. The increased incidence of neoplasms in the urinary bladder and kidney of rats was also associated with an increase in the <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculi</span> formation and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> of transitional cell epithelium. For the mouse study, sulfasalazine was tested at 675 (2025 mg/m²), 1350 (4050 mg/m²), and 2700 (8100 mg/m²) mg/kg/day. The incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> or carcinoma in male and female mice was significantly greater than the control at all doses tested.</p>
<p>Sulfasalazine did not show mutagenicity in the bacterial reverse mutation assay (Ames test) and in L51784 mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay at the HGPRT gene. However, sulfasalazine showed equivocal mutagenic response in the micronucleus assay of mouse and rat bone marrow and mouse peripheral RBC and in the sister chromatid exchange, chromosomal aberration, and micronucleus assays in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> obtained from humans.</p>
<p>Impairment of male fertility was observed in reproductive studies performed in rats at a dose of 800 mg/kg/day (4800 mg/m²). <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> have been described in men treated with sulfasalazine. Withdrawal of the drug appears to reverse these effects.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_86c31707-79de-4051-ac9f-7fead09eb423"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">Pregnancy:</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_af2b5d3b-0a3f-499c-a881-e4132d89e271"></a><a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<p class="First"><span class="Bold">Pregnancy Category B. </span>Reproduction studies have been performed in rats and rabbits at doses up to 6 times the human dose and have revealed no evidence of impaired female fertility or harm to the fetus due to sulfasalazine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. A national survey evaluated the outcome of pregnancies associated with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (IBD). In a group of 186 women treated with sulfasalazine alone or sulfasalazine and concomitant steroid therapy, the incidence of fetal morbidity and mortality was comparable to that for 245 untreated IBD pregnancies as well as to pregnancies in the general population.¹ A study of 1,455 pregnancies associated with exposure to sulfonamides indicated that this group of drugs, including sulfasalazine, did not appear to be associated with <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span>.² A review of the medical literature covering 1,155 pregnancies in women with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> suggested that the outcome was similar to that expected in the general population.³</p>
<p>No clinical studies have been performed to evaluate the effect of sulfasalazine on the growth development and functional maturation of children whose mothers received the drug during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_571bd110-8640-43ab-876d-68c34736555b"></a><a name="section-6.7.2"></a><p></p>
<h3>Nonteratogenic Effects:</h3>
<p class="First">Sulfasalazine and sulfapyridine pass the placental barrier. Although sulfapyridine has been shown to have a poor bilirubin-displacing capacity, the potential for <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in newborns should be kept in mind.</p>
<p>A case of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> has been reported in an infant whose mother was taking both sulfasalazine and prednisone throughout pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_0ae8176b-9579-451e-834e-dc31cce0a5a5"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Sulfonamides, including sulfasalazine, are excreted in human milk. In the newborn, sulfonamides compete with bilirubin for binding sites on the plasma proteins and may cause <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>. Insignificant amounts of uncleaved sulfasalazine have been found in milk, whereas the sulfapyridine levels in milk are about 30 to 60 percent of those in the maternal serum. Sulfapyridine has been shown to have a poor bilirubin-displacing capacity. Caution should be exercised when sulfasalazine is administered to a nursing mother. </p>
<p>There have been five reports with limited data of <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in human milk fed infants of mothers taking sulfasalazine. In cases where the outcome was reported, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolved in the infant after discontinuation of sulfasalazine in the mother or discontinuation of breastfeeding. A causal relationship between infants exposed to sulfasalazine through human milk and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> cannot be determined from the limited data, but an association cannot be ruled out either. Consider monitoring human milk fed infants of mothers taking sulfasalazine for signs and symptoms of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and/or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_b7526e6f-0011-449d-a1e7-ab727ba3606f"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">Pediatric Use:</span></h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of two years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_05845933-f9bf-47f8-8c6d-4e7531598845"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The most common adverse reactions associated with sulfasalazine are <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric distress, and apparently reversible <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>. These occur in about one-third of the patients. Less frequent adverse reactions are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, Heinz body <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, which may occur at a frequency of one in every thirty patients or less. Experience suggests that with a daily dosage of 4 g or more, or total serum sulfapyridine levels above 50 µg/mL, the incidence of adverse reactions tends to increase.</p>
<p>Although the listing which follows includes a few adverse reactions which have not been reported with this specific drug, the pharmacological similarities among the sulfonamides require that each of these reactions be considered when sulfasalazine tablets are administered. Less common or rare adverse reactions include:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span>: </span><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, megaloblastic (macrocytic) <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, congenital <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: </span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">epidermal necrolysis</span> (Lyell’s syndrome) with corneal damage, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> syndrome, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> with or without <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4025168" conceptname="Diffuse interstitial pulmonary fibrosis">fibrosing alveolitis</span>, <span class="product-label-link" type="condition" conceptid="78786" conceptname="Pleurisy">pleuritis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> with or without tamponade, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">polyarteritis nodosa</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>-like syndrome, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> with or without immune complexes, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, sometimes leading to liver transplantation, <span class="product-label-link" type="condition" conceptid="320798" conceptname="Parapsoriasis">parapsoriasis</span> varioliformis acuta (Mucha-Haberman syndrome), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, photosensitization, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, conjunctival and scleral injection, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
<p><span class="Bold">Gastrointestinal reactions: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, impaired folic acid absorption, impaired digoxin absorption, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pains</span>, and <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic enterocolitis</span>.</p>
<p><span class="Bold">Central nervous system reactions: </span>transverse <span class="product-label-link" type="condition" conceptid="138965" conceptname="Myelitis">myelitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, transient lesions of the posterior spinal column, <span class="product-label-link" type="condition" conceptid="4102342" conceptname="Cauda equina syndrome">cauda equina syndrome</span>, Guillian-Barre syndrome, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.</p>
<p><span class="Bold">Renal reactions: </span>toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and hemolytic-<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremic syndrome</span>.</p>
<p><span class="Bold">Other reactions: </span><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span> and <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>.</p>
<p>The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides), and oral hypoglycemic agents. <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span> production, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have occurred rarely in patients receiving sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides and long-term administration has produced thyroid malignancies in this species.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_13f9dddf-00fc-4de6-8ad0-3e3634907710"></a><a name="section-7.1"></a><p></p>
<h2>Postmarketing Reports</h2>
<p class="First">The following events have been identified during post-approval use of products which contain (or are metabolized to) mesalamine in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to mesalamine:</p>
<p><span class="Bold">Gastrointestinal: </span>Reports of hepatotoxicity, including elevated liver function tests (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, cirrhosis, and possible <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these cases were fatal. One case of Kawasaki-like syndrome, which included hepatic function changes, was also reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_15b61452-9019-4f22-b649-e430f8bc0c03"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<p class="First">None reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c40849ce-917e-42f7-b62d-61c678fc58ef"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">There is evidence that the incidence and severity of toxicity following overdosage are directly related to the total serum sulfapyridine concentration. Symptoms of overdosage may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric distress, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pains</span>. In more advanced cases, central nervous system symptoms such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, etc., may be observed. Serum sulfapyridine concentrations may be used to monitor the progress of recovery from overdosage.</p>
<p>There are no documented reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to ingestion of large single doses of sulfasalazine. Doses of sulfasalazine tablets of 16 g per day have been given to patients without mortality. A single oral dose of 12 g/kg was not lethal to mice.</p>
<p><span class="Bold">Instructions for Overdosage: </span>Gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> plus catharsis as indicated. Alkalinize urine. If kidney function is normal, force fluids. If <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> is present, restrict fluids and salt, and treat appropriately. Catheterization of the ureters may be indicated for complete renal blockage by crystals. The low molecular weight of sulfasalazine and its metabolites may facilitate their removal by dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_9a24b8e3-adff-433e-a8a9-9ef6d40b98f5"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">The dosage of sulfasalazine tablets should be adjusted to each individual’s response and tolerance.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e7191fdc-c6da-4fbb-994e-8b46b57d96eb"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold">Initial Therapy:</span></h2>
<p class="First">Adults<span class="Italics">:</span> 3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours. In some cases, it is advisable to initiate therapy with a smaller dosage, e.g., 1 to 2 g daily, to reduce possible gastrointestinal intolerance. If daily doses exceeding 4 g are required to achieve desired effects, the increased risk of toxicity should be kept in mind. </p>
<p>Children, six years of age and older: 40 to 60 mg/kg body weight in each 24-hour period, divided into 3 to 6 doses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_48656204-cda8-4062-8bdf-8b2bdc47f36c"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold">Maintenance Therapy:</span></h2>
<p class="First">Adults<span class="Italics">:</span> 2 g daily.</p>
<p>Children, six years of age and older: 30 mg/kg body weight in each 24-hour period, divided into 4 doses.</p>
<p>The response of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span> to sulfasalazine tablets can be evaluated by clinical criteria, including the presence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, weight changes, and degree and frequency of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as well as by sigmoidoscopy and the evaluation of biopsy samples. It is often necessary to continue medication even when clinical symptoms, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been controlled. When endoscopic examination confirms satisfactory improvement, the dosage of sulfasalazine should be reduced to a maintenance level. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> recurs, the dosage should be increased to previously effective levels. If symptoms of gastric intolerance (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, etc.) occur after the first few doses of sulfasalazine, they are probably due to increased serum levels of total sulfapyridine and may be alleviated by halving the daily dose of sulfasalazine and subsequently increasing it gradually over several days. If gastric intolerance continues, the drug should be stopped for 5 to 7 days, then reintroduced at a lower daily dose.</p>
<p>Some patients may be sensitive to treatment with sulfasalazine. Various desensitization-like regimens have been reported to be effective in 34 of 53 patients,<span class="Sup"> 4</span> 7 of 8 patients,<span class="Sup"> 5</span> and 19 of 20 patients.<span class="Sup"> 6</span> These regimens suggest starting with a total daily dose of 50 to 250 mg sulfasalazine initially, and doubling it every 4 to 7 days until the desired therapeutic level is achieved. If the symptoms of sensitivity recur, sulfasalazine should be discontinued. </p>
<p>Desensitization should not be attempted in patients who have a history of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, or who have experienced an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> while previously receiving sulfasalazine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_5964f202-b07c-4283-83e8-d0e1d4166988"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Sulfasalazine Tablets, USP, 500 mg are round, mustard-colored, biconvex, imprinted "<span class="Bold">WATSON</span>"and "<span class="Bold">796</span>"on one side and partial bisect on the other side. They are available in the following package sizes:<br><br>Bottles of 100              NDC 0591-0796-01<br>Bottles of 500              NDC 0591-0796-05<br>Bottles of 1000            NDC 0591-0796-10<br><br>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_5e9e977e-8eb0-4f5f-805f-b9789aa6e191"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol class="Arabic">
<li>Mogadam M, et al. Pregnancy in <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6.</li>
<li>Kaufman DW, editor. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> and drugs during pregnancy. Littleton, MA: Publishing Sciences Group, Inc, 1977;296-313.</li>
<li>Jarnerot G. Fertility, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> and pregnancy in chronic <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>. Scand J Gastroenterol 1982;17:1-4.</li>
<li>Korelitz B, et al. Desensitization to sulfasalazine in allergic patients with IBD: an important therapeutic modality. Gastroenterology 1982;82:1104.</li>
<li>Holdworth CG. Sulphasalazine desensitization. Br Med J 1981;282:110.</li>
<li>Taffet SL, Das KM. Desensitization of patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> to sulfasalazine. Am J Med 1982;73:520-4.</li>
</ol>
<p class="First"><span class="Bold">Manufactured for:<br></span>Watson Laboratories, Inc.<br>Corona, CA 92880 USA</p>
<p><span class="Bold">Manufactured by:<br></span>Patheon Pharmaceuticals Inc.<br>Cincinnati, OH 45237 USA</p>
<p>Revised: December 2012    <br><br>70027072</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_81cceb0f-4d8e-44ed-83bf-86931bcbe068"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">0591-0796-01<br>Sulfasalazine <br>Tablets USP<br>500 mg<br>Watson   100 Tablets   Rx only<br><br><span class="Bold">Each tablet contains:<br></span>Sulfasalazine USP, 500 mg</p>
<p><span class="Bold">Usual dosage:</span> See package outsert for full prescibing information.<br><br><span class="Bold">Dispense</span> in a well-closed containter as defined in USP/NF.<br><br><span class="Bold">Store</span> at 20ºC-25ºC (68º-77ºF). [See USP controlled room temperature.]<br><br><span class="Bold">Keep out of reach of children.<br></span><br>Manufactured By:<br><span class="Bold">Patheon Pharmaceuticals Inc.<br></span>Cincinnati, OH 45237 USA                            (12/06)<br><br>Distributed By: <br><span class="Bold">Watson Pharma, Inc                                  </span>      70015116<br><br><img alt="0591-0796-01 Sulfasalazine Tablets USP 500 mg Watson 100 Tablets Rx only" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad13d598-7b1b-48d3-a25b-08635b419f99&amp;name=sulfasalazine-tablets-usp-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFASALAZINE 		
					</strong><br><span class="contentTableReg">sulfasalazine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-0796</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFASALAZINE</strong> (SULFASALAZINE) </td>
<td class="formItem">SULFASALAZINE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (mustard) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;796</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-0796-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0591-0796-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0591-0796-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085828</td>
<td class="formItem">10/01/1982</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Watson Laboratories, Inc.
							(106931488)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">ANALYSIS(0591-0796), LABEL(0591-0796), MANUFACTURE(0591-0796), PACK(0591-0796)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>46c7c990-da20-442b-b147-f7da6272de45</div>
<div>Set id: ad13d598-7b1b-48d3-a25b-08635b419f99</div>
<div>Version: 9</div>
<div>Effective Time: 20130325</div>
</div>
</div> <div class="DistributorName">Watson Laboratories, Inc.</div></p>
</body></html>
